JPMorgan downgraded Biomea Fusion (BMEA) to Underweight from Neutral without a price target The firm views the recent phase 2 COVALENT II icovamenib data in type 2 diabetes as “interesting” but has concerns around the company’s ability to fund the ongoing and planned studies. The funding may come with significant dilution over the long-term without a partnership, which is difficult to predict, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion price target lowered to $6 from $7 at Citi
- Biomea Fusion announces presentation of two posters for BMF-650, icovamenib
- Biomea Fusion price target lowered to $12 from $16 at D. Boral Capital
- Biomea Fusion Inc. Reports Q3 2025 Financial Results
- Biomea Fusion reports Q3 EPS (27c), consensus (29c)